PT  - JOURNAL ARTICLE
AU  - L. D. Wilkerson
AU  - R. P. Lisak
AU  - B. Zweiman
AU  - D. H. Silberberg
TI  - Antimyelin antibody in multiple sclerosis: no change during immunosuppression
AID  - 10.1136/jnnp.40.9.872
DP  - 1977 Sep 01
TA  - Journal of Neurology, Neurosurgery & Psychiatry
PG  - 872--875
VI  - 40
IP  - 9
4099  - http://jnnp.bmj.com/content/40/9/872.short
4100  - http://jnnp.bmj.com/content/40/9/872.full
SO  - J Neurol Neurosurg Psychiatry1977 Sep 01; 40
AB  - We studied retrospectively levels of antimyelin antibody in a group of 13 multiple sclerosis patients who underwent a clinical trial of long-term, high dose (2.0-4.5 mg/kg/day) azathiaprine therapy. In apparent contrast with collagen vascular disease associated with antitissue antibody, azathiaprine therapy was not associated with significant change in titres of antimyelin antibody. Variation of titre of antimyelin antibody in apparent association with disease activity continued during therapy. No significant changes occurred in levels of serum immunoglobulins.